Fig 5 - by Te-Hsing Hsu (16973374)

Flowchart of study selection. by Alejandro Piscoya (782326)

Subjects:

Effect of remdesivir on invasive ventilation at 14 days. by Alejandro Piscoya (782326)

Subjects:

Effect of remdesivir on all-cause mortality at 14 days. by Alejandro Piscoya (782326)

Subjects:

Summary of findings table for the comparison remdesivir 5 days vs. standard of care for hospitalized, moderate COVID-19. by Alejandro Piscoya (782326)

Subjects:

Description of characteristics of included studies. by Alejandro Piscoya (782326)

Subjects:

Summary of findings table for the comparison remdesivir 10 days vs. placebo for hospitalized, severe COVID-19. by Alejandro Piscoya (782326)

Subjects:

Summary of findings table for the comparison of remdesivir 5 days vs. remdesivir 10 days for hospitalized, severe COVID-19. by Alejandro Piscoya (782326)

Subjects:

Metformin pre-treatment retains an antioxidant effect and decreases apoptosis, in an AMPK activation manner. by Silvia Siteni (10344070)

Fig 3 - by Nida Mansoora (11648641)

Subjects:

Fig 2 - by Nida Mansoora (11648641)

Subjects:

Fig 4 - by Nida Mansoora (11648641)

Subjects:

Fig 1 - by Nida Mansoora (11648641)

Subjects:

Fig 5 - by Saeed El-Ashram (710370)

Fig 5 - by Wenping Dong (3854437)

Subjects:

rt-PA-induced lysis of different clot sizes. by Jan Víteček (11434774)

The dependency of thrombolysis on rt-PA concentration. by Jan Víteček (11434774)

Complete data. by Jan Víteček (11434774)

“…The rt-PA became increasingly less efficient for clots larger than 50 μl at a clinically relevant concentration of 1.3 mg/l. …”

Fig 4 - by Jan Víteček (11434774)

“…The rt-PA became increasingly less efficient for clots larger than 50 μl at a clinically relevant concentration of 1.3 mg/l. …”

Number and distribution of the participants in the Tromsø Study surveys Tromsø5, Tromsø6 and Tromsø7. by Saija Mikkilä (12004053)

Subjects: